Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (16.667%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Update on CFO Appointment

29 Nov 2016 07:00

RNS Number : 3503Q
Genedrive PLC
29 November 2016
 

 

 

For release: 29 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

Update on CFO Appointment

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

 

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

 

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGGUGUPQGMR
Date   Source Headline
23rd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20203:13 pmRNSHolding(s) in Company
21st Jul 202011:05 amRNSSecond Price Monitoring Extn
21st Jul 202011:00 amRNSPrice Monitoring Extension
16th Jul 20204:29 pmRNSHolding(s) in Company
13th Jul 20209:00 amRNSPrice Monitoring Extension
10th Jul 20202:05 pmRNSSecond Price Monitoring Extn
10th Jul 20202:00 pmRNSPrice Monitoring Extension
10th Jul 20207:01 amRNSNew Genedrive® 96 Exporter software
10th Jul 20207:00 amRNSTrading update
1st Jul 20207:00 amRNSTotal Voting Rights
26th Jun 20203:24 pmRNSHolding(s) in Company
25th Jun 20203:39 pmRNSHolding(s) in Company
22nd Jun 20203:06 pmRNSHolding(s) in Company
22nd Jun 202011:08 amRNSHolding(s) in Company
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
17th Jun 20204:41 pmRNSSecond Price Monitoring Extn
17th Jun 20204:35 pmRNSPrice Monitoring Extension
17th Jun 20202:05 pmRNSSecond Price Monitoring Extn
17th Jun 20202:00 pmRNSPrice Monitoring Extension
16th Jun 202011:37 amRNSConversion of Convertible Bond
15th Jun 20204:40 pmRNSSecond Price Monitoring Extn
15th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20207:00 amRNSInvestor presentation
9th Jun 20204:41 pmRNSSecond Price Monitoring Extn
9th Jun 20204:36 pmRNSPrice Monitoring Extension
9th Jun 20202:06 pmRNSSecond Price Monitoring Extn
9th Jun 20202:00 pmRNSPrice Monitoring Extension
9th Jun 202011:05 amRNSSecond Price Monitoring Extn
9th Jun 202011:00 amRNSPrice Monitoring Extension
29th May 20203:02 pmRNSHolding(s) in Company
29th May 202012:19 pmRNSHolding(s) in Company
29th May 202011:49 amRNSHolding(s) in Company
29th May 20208:30 amRNSHolding(s) in Company
28th May 20202:06 pmRNSSecond Price Monitoring Extn
28th May 20202:01 pmRNSPrice Monitoring Extension
28th May 20201:18 pmRNSApplication for Block Listing
28th May 202012:50 pmRNSHolding(s) in Company
28th May 202011:05 amRNSSecond Price Monitoring Extn
28th May 202011:00 amRNSPrice Monitoring Extension
27th May 202011:35 amRNSResult of General Meeting
27th May 20208:15 amRNSHolding(s) in Company
26th May 202011:58 amRNSHolding(s) in Company
26th May 20209:30 amRNSHolding(s) in Company
22nd May 202011:05 amRNSSecond Price Monitoring Extn
22nd May 202011:00 amRNSPrice Monitoring Extension
22nd May 20209:05 amRNSSecond Price Monitoring Extn
22nd May 20209:00 amRNSPrice Monitoring Extension
22nd May 20207:00 amRNSGenedrive 96 SARS-CoV-2 Kit receives CE-IVD Mark

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.